Vericiguat for Heart Failure with Reduced Ejection Fraction

[1] Metra M(2017)Heart failure Lancet 390 1981-1995

[2] Teerlink JR(2016)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 18 891-975

[3] Ponikowski P(2019)Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis Eur J Heart Fail 21 1306-1325

[4] Jones NR(2016)European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions Eur J Heart Fail 18 613-625

[5] Roalfe AK(2014)Highlights in heart failure J Am Coll Cardiol 63 1123-1133

[6] Adoki I(2019)The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction ESC Heart Failure 6 1105-1127

[7] Hobbs FDR(2018)Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Cardiovasc Ther 36 e12435-1073

[8] Taylor CJ(2013)Angiotensin-neprilysin inhibition in acute decompensated heart failure Eur J Heart Fail 15 1062-548

[9] Crespo-Leiro MG(2019)Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review N Engl J Med 380 539-49

[10] Anker SD(2018)SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials Rev Cardiovasc Med 19 41-829

[1] Metra M(2017)Heart failure Lancet 390 1981-1995

[2] Teerlink JR(2016)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 18 891-975

[3] Ponikowski P(2019)Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis Eur J Heart Fail 21 1306-1325

[4] Jones NR(2016)European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions Eur J Heart Fail 18 613-625

[5] Roalfe AK(2014)Highlights in heart failure J Am Coll Cardiol 63 1123-1133

[6] Adoki I(2019)The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction ESC Heart Failure 6 1105-1127

[7] Hobbs FDR(2018)Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Cardiovasc Ther 36 e12435-1073

[8] Taylor CJ(2013)Angiotensin-neprilysin inhibition in acute decompensated heart failure Eur J Heart Fail 15 1062-548

[9] Crespo-Leiro MG(2019)Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review N Engl J Med 380 539-49

[10] Anker SD(2018)SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials Rev Cardiovasc Med 19 41-829